| Literature DB >> 29160347 |
Ezgi Atik1, Tülin Taner2.
Abstract
OBJECTIVE: The aim of this study was to compare the longitudinal stability of the conventional straight-wire system after the use of a quad-helix appliance with Damon self-ligating system in patients with Class I malocclusion.Entities:
Mesh:
Year: 2017 PMID: 29160347 PMCID: PMC5730139 DOI: 10.1590/2177-6709.22.5.075-082.oar
Source DB: PubMed Journal: Dental Press J Orthod ISSN: 2176-9451
Demographic and clinical characteristics of the sample.
| Variables | Group 1 (Damon) | Group 2 (Conventional) | p-value |
| Number of subjects | 12 | 15 | |
| Age (year) | 14.65 (13.10-16.70) | 14.80 (12.10-15.90) | 0.905a |
| Mand. crowding (mm) | 3.75±0.94 | 3.31±0.74 | 0.256a |
| Max. crowding (mm) | 4.24±1.14 | 3.66±0.90 | 0.236a |
a: Mann-Whitney test. Values are presented as mean ± standard deviation (SD), median (min-max) or p-value.
Figure 1Lateral cephalometric dental angular and linear measurements: 1) U1-SN (degrees); 2) U1-FH (degrees); 3) U1-NA (degrees); 4) U1-NA (mm); 5) IMPA (degrees); 6) FMIA (degrees); 7) L1-NB (degrees); 8) L1-NB (mm).
Figure 2Posteroanterior cephalometric measurements: 1) UR6-ML (degrees); 2) UR6-ML (mm); 3) UL6-ML (degrees); 4) UL6-ML (mm); 5) UR6-UL6 (mm).
Figure 31) Inter-canine width (3-3), which is the distance between the right and left maxillary canine cusp tips. 2) Inter-first premolar width (4-4), which is the distance between the buccal cusp tips of the right and left maxillary first premolars. 3) Inter-second premolar width (5-5), which is the distance between the buccal cusp tips of the right and left maxillary second premolars. 4) Inter-molar width (6-6), which is the distance between the mesiobuccal cusp tips of the right and left maxillary first molars.
Dental Model Meausurements of the Groups at T1 (pre-treatment) ,T2 (post-treatment) and T3 (3 years post-treatment) Periods
| Variables | T1 | T2 | T3 | T2-T1 | T3-T2 | T3-T1 | |
| mean±SD | mean±SD | mean±SD | pa | pa | pa | pb | |
| 3-3 | 0,647 | ||||||
| Group 1 (Damon) | 33.83±3.54 | 35.99±2.41 | 34.81±2.34 | 0.001* | 0.007* | 1.000 | |
| Group 2 (Conventional) | 32.861±3.15 | 34.94±1.93 | 34.08±1.20 | 0.0001* | 0.019* | 0.301 | |
| 4-4 | 0.438 | ||||||
| Group 1 (Damon) | 38.16±2.95 | 43.58±2.13 | 42.35±1.98 | 0.0001* | 0.662 | 0.007* | |
| Group 2 (Conventional) | 38.09±2.32 | 44.03±2.06 | 42.24±2.20 | 0.0001* | 0.019* | 0.019* | |
| 5-5 | 0.462 | ||||||
| Group 1 (Damon) | 42.82±3.49 | 48.28±2.76 | 47.16±2.30 | 0.0001* | 0.662 | 0.007* | |
| Group 2 (Conventional) | 43.79±3.38 | 49.12±2.26 | 47.47±2.49 | 0.0001* | 0.053 | 0.010* | |
| 6-6 | 0.976 | ||||||
| Group 1 (Damon) | 48.85±3.73 | 52.70±3.34 | 51.75±2.89 | 0.0001* | 0.662 | 0.007* | |
| Group 2 (Conventional) | 49.90±3.90 | 53.77±2.91 | 52.73±3.18 | 0.0001* | 0.134 | 0.006* |
*Statistically significant (p< 0,05).
a: Friedman test, comparison of pre-treatment, post-treatment and 3 years post-treatment measurements within the groups.
b: Two-way repeated ANOVA measure test, comparison of groups.
Postero-anterior cephalometric measurements of the groups at T1 (pre-treatment), T2 (post-treatment) and T3 (3 years post-treatment) periods.
| Variables | T1 | T2 | T3 | T2-T1 | T3-T2 | T3-T1 | |
| mean±SD/ median (min-max) | mean±SD/ median (min-max) | mean±SD | pa | pa | pa | pb | |
| UR6-ML (mm) | 0,252 | ||||||
| Group 1 | 27.98±1.86 | 29.86±2.18 | 26.53±1.41 | 0.013* | 0.0001* | 0.922 | |
| Group 2 | 30.13±1.79 | 31.23±2.22 | 27.98±2.73 | 0.019* | 0.000* | 0.301 | |
| UR6-ML (degrees) | 0.164 | ||||||
| Group 1 | 24.47±2.97 | 30.01±2.67 | 24.26±3.03 | 0.013* | 0.0001* | 0.922 | |
| Group 2 | 26.96 (16.18-30.64) | 29.61 (20.57-31.77) | 24.52±3.49 | 0.003* | 0.0001* | 1.000 | |
| UL6-ML (mm) | 0.501 | ||||||
| Group 1 | 28.57±1.22 | 29.61±1.23 | 26.33±0.99 | 0.074 | 0.0001* | 0.074 | |
| Group 2 | 29.31±2.10 | 30.78±1.74 | 27.53±2.53 | 0.010* | 0.0001* | 0.604 | |
| UL6-ML (degrees) | 0.055 | ||||||
| Group 1 | 27.62±3.64 | 31.68±3.03 | 26.20±4.12 | 0.002* | 0.0001* | 1.000 | |
| Group 2 | 26.79±3.82 | 29.44±2.97 | 26.73±2.32 | 0.002* | 0.006* | 1.000 | |
| UR6-UL6 (mm) | 0.831 | ||||||
| Group 1 | 56.97±2.64 | 59.34±2.80 | 53.71±2.16 | 0.043* | 0.0001* | 0.199 | |
| Group 2 | 59.59±3.45 | 61.73±3.56 | 56.62±5.40 | 0.002* | 0.0001* | 1.000 |
*Statistically significant (p< 0,05).
a: Friedman test, comparison of pre-treatment, post-treatment and 3 years post-treatment measurements within the groups.
b: Two-way repeated ANOVA measure test, comparison of groups.
Lateral cephalometric measurements of the groups at T1 (pre-treatment), T2 (post-treatment) and T3 (3 years post-treatment) periods.
| Variables | T1 | T2 | T3 | T2-T1 | T3-T2 | T3-T1 | |
| mean±SD | mean±SD | mean±SD | pa | pa | pa | pb | |
| U1-SN (degrees) | 0,173 | ||||||
| Group 1 | 102.47±8.41 | 107.07±7.35 | 106.92±5.70 | 0.007* | 1.000 | 0.043* | |
| Group 2 | 102.00±7.17 | 103.48±5.73 | 103.40±7.50 | 0.448 | 1.000 | 0.08 | |
| U1-FH (degrees) | 0.342 | ||||||
| Group 1 | 112.76±7.20 | 116.99±6.09 | 116.80±5.48 | 0.024* | 1.000 | 0.074 | |
| Group 2 | 111.86±6.70 | 113.09±5.54 | 114.12±6.37 | 0.432 | 0.706 | 0.024* | |
| U1-NA (degrees) | 0.386 | ||||||
| Group 1 | 22.08±7.80 | 27.00±5.30 | 27.42±6.10 | 0.074 | 1 | 0.124 | |
| Group 2 | 22.86±6.65 | 25.16±5.16 | 25.16±7.29 | 0.018* | 0.523 | 0.083 | |
| U1-NA (mm) | 0.45 | ||||||
| Group 1 | 4.64±2.59 | 6.06±1.61 | 6.15±1.46 | 0.074 | 1.000 | 0.024* | |
| Group 2 | 5.13±2.18 | 5.86±2.45 | 5.64±2.18 | 0.053 | 1 | 0.249 | |
| IMPA (degrees) | 0.867 | ||||||
| Group 1 | 95.70±3.58 | 101.41±6.24 | 100.50±5.30 | 0.074 | 0.922 | 0.003* | |
| Group 2 | 92.95±6.43 | 97.56±7.70 | 97.35±7.92 | 0.019* | 1.000 | 0.019* | |
| FMIA (degrees) | 0.764 | ||||||
| Group 1 | 61.27±6.97 | 54.05±6.78 | 55.91±8.31 | 0.024* | 1 | 0.013* | |
| Group 2 | 62.47±6.24 | 56.56±6.71 | 57.66±7.66 | 0.002* | 1 | 0.002* | |
| L1-NB (degrees) | 0.702 | ||||||
| Group 1 | 26.08±4.72 | 32.55±5.14 | 30.90±6.11 | 0.002* | 1.000 | 0.003* | |
| Group 2 | 23.84±5.90 | 28.77±6.58 | 27.98±7.18 | 0.002* | 1.000 | 0.006* | |
| L1-NB (mm) | 0.128 | ||||||
| Group 1 | 5.40±2.65 | 7.77±2.58 | 7.41±3.01 | 0.001* | 1.000 | 0.007* | |
| Group 2 | 5.17±2.22 | 6.76±2.37 | 6.17±2.50 | 0.000* | 0.134 | 0.067 |
*Statistically significant (p< 0,05).
a: Friedman test, comparison of pre-treatment, post-treatment and 3 years post-treatment measurements within the groups.
b: Two-way repeated ANOVA measure test, comparison of groups.